Emotion regulation individual therapy
BehavioralThe emotion regulation individual therapy is delivered via an internet platform and includes therapist contact several times per week via the platform.
NCT Number: NCT03353961
To evaluate if Internet delivered emotion regulation individual therapy for adolescents is an efficacious treatment when delivered as adjunctive to treatment as usual compared to a control group consisting of treatment as usual.
Looking for future studies?
Notify Me13 year–17 year
All sexes
Interventional
Not applicable
Centre for Psychiatry Research Karolinska Institutet and Stockholm County Council, Stockholm, Sweden
Statistical Analyses
Treatment effects will be evaluated according to the intention-to-treat principle. Primary end-point for all outcomes is post-treatment. Secondary end-point include a controlled 3 month follow-up.
Primary Analysis
The primary outcome analysis will include treatment group (ERITA , TAU) and weekly reports of NSSI frequency measured once every week 4 weeks prior to treatment start, once every week during treatment, and once every week four weeks after treatment termination. Regression analysis modelled for count data will be used to estimate trend over time. Four weeks after treatment termination will be considered primary endpoint. Pairwise contrasts (group x time interaction) from the regression model will be used to evaluate between-group differences at primary endpoint (4 weeks after treatment termination).
Secondary Analyses
Secondary outcomes measured once before, during, and after treatment will be analyzed in a similar fashion as for the primary outcome, modelled after data's distribution (count or continuous). Measures collected only once at baseline and post-treatment will be analyzed with regression analyses including treatment group (online ERITA , TAU) as the between-subjects factor, time (baseline to post) as the within-subjects factor, and group × time interactions, modelled after data's distribution (count or continuous).
Parallel process latent growth curve modeling will be used to determine whether change in week-to-week emotion dysregulation (DERS-16) during treatment mediate the overall effect of ERITA+ETAU on week-to-week change in the primary outcome self-rated NSSI frequency (DSHI-Y).
3 Month Follow-Up
Data collected at 3-month follow-up will be used to determine the extent to which potential treatment gains were maintained both within and between treatment conditions
Update 28 April 2022: As a secondary analyses, we also aim to investigate the effect of treatment moderators (primary aim) and predictors (secondary aim) on NSSI frequency one month after treatment termination. This update was submitted prior to conducting the analyses.
The selection of potential moderators was theoretically and empirically motivated. We will investigate the following variables (measured at baseline):
Age Difficulties in emotion regulation As measured with the Difficulties in Emotion Regulation Scale - 36 item version (DERS) Past month NSSI frequency As measured with the Deliberate Self-Harm Inventory Youth version (DSHI-Y) Global functioning As measured with the Childrens Global Assessment Scale Depressive symptoms As measured with the 21-item Depression Anxiety Stress Scales (DASS-21) Sleep difficulties As measured with the Insomnia Severity Index (ISI) Parental Minimization - discounting or devaluing the child's negative emotions/problems As measured with The Coping with Children's Negative Emotions Scale Adolescent Version (CCNES-A), subscale minimazation Level of suicidality As measured with the MINI-KID International Neuropsychiatric Interview, version 6
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The emotion regulation individual therapy is delivered via an internet platform and includes therapist contact several times per week via the platform.
Treatment as usual as provided in the community.
Time frame: Change from baseline, once every week during treatment (0-12 weeks after baseline), 3 and 12 months after treatment has ended
Frequency of nonsuicidal self-injury
Time frame: Change from baseline, once every week during treatment (0-12 weeks after baseline), 3 and 12 months after treatment has ended
Difficulties in emotion regulation as primary potential mechanism of change. Ranges from 16-80, with higher scores indicating more difficulties.
Time frame: Change from baseline, 12 weeks after treatment starts, 3 and 12 months after treatment has ended
Difficulties in emotion regulation. Ranges from 36-180, with higher scores indicating more difficulties.
Time frame: Change from baseline, 12 weeks after treatment starts, 3 and 12 months after treatment has ended
Symptoms of depression, anxiety and stress. Each subscale (depression, anxiety and stress) ranges from 0-21, with higher scores indicating more symptoms.
Time frame: Change from baseline, once every week during treatment (0-12 weeks after baseline), 3 and 12 months after treatment has ended
Impulsive self-destructive behaviors
Time frame: Change from baseline, 12 weeks after treatment starts, 3 and 12 months after treatment has ended
Acceptance and valued actions. Ranges from 7-49, with higher scores indicating less acceptance and valued actions.
Time frame: Change from baseline, 16 weeks after treatment starts, 3 months after treatment has ended
Global functioning. Ranges from 1-100, with higher scores indicating better functioning.
Time frame: Change from baseline, 16 weeks after treatment starts, 3 months after treatment has ended
Global symptom severity and improvement. Severity of illness scale ranges from 1-7, with higher scores indicating higher severity of illness. Global improvement scale ranges from 1-7 with lower scores indicating more improvement.
Time frame: Change from baseline, once every second week during treatment (0-12 weeks after baseline)
Experiences in close relationships. Ranges from 12-84, with higher scores indicating greater problems.
Time frame: Change from baseline, once every second week during treatment (0-12 weeks after baseline)
Worry. Ranges 0-21, with higher scores indicating more worry.
Time frame: Change from baseline, 12 weeks after treatment starts, 3 and 12 months after treatment has ended
Costs associated with psychiatric illness
Time frame: Change from baseline, 12 weeks after treatment starts, 3 and 12 months after treatment has ended
Quality of life. Ranges 11-55, with higher scores indicating higher quality in life.
Time frame: 6 and 12 weeks after baseline
Patient adherence to treatment. Ranges from 0-20, with higher scores indicating higher adherence.
Time frame: 4 weeks after treatment starts
Working alliance with online therapist
Time frame: Change from baseline, 6 and 12 weeks after treatment starts, 3 and 12 months after treatment has ended
Parents' perceived ability to cope with children's negative emotions. Three subscales will be used derived to reflect the specific types of coping response parents tend to use in these situations (punitive reactions, problem focused reactions, and minimization reactions). Each subscale ranges from 1-7.
Time frame: 12 weeks after treatment starts
Client satisfaction with treatment. Ranges from 8-32 with higher scores indicating greater treatment satisfaction.
Time frame: 12 weeks after treatment starts
Self-rating scale that measures adverse events related to treatment
Time frame: 1 week after treatment starts
Treatment credibility and expectancy. Ranges from 0-50 with higher scores indicating greater credibility/expectancy.
Karolinska Institutet
Other
Internet Delivered Emotion Regulation Individual Therapy for Adolescents With Nonsuicidal Self-Injury: A Randomized Controlled Study
Acronym: ERITA
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05608304
Behavior, Behavioral Symptoms
Montreal, Quebec, Canada
View Trial DetailsNCT06038942
ADHD, Attention Deficit Disorder with Hyperactivity
Montreal, Quebec, Canada
View Trial DetailsNCT03655470
Behavior, Behavioral Symptoms
Providence, Rhode Island, United States
View Trial DetailsNCT05935345
Behavior, Behavioral Symptoms
Linköping, Östergötland County, Sweden
View Trial Details